Overview

A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

This is a single-center, partial-blind, randomized, placebo-controlled, parallel design study with a nested crossover comparison to define the ECG effects of tizanidine compared to placebo and the positive control, moxifloxacin, in healthy men and women. The study will be conducted in a Phase 1 unit with sufficient facilities to house subjects as required by the protocol.

Phase:

Phase 2

Details

Lead Sponsor:

Acorda Therapeutics

Treatments:

Clonidine
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Tizanidine